04.24.07 First Berlin Releases Research Update Following Callisto Pharmaceutical’s 2006 Fiscal Year Results and Pipeline update
04.24.07 Rodman And Renshaw Releases Research Update Following Callisto Pharmaceutical’s Announcement Of Initiation Of Phase II Trial In Advanced Carcinoid Cancer Patients
04.16.07 Callisto Reports on 2006 and First-Quarter 2007 Clinical and Corporate Milestones and Achievements
04.11.07 Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
04.05.07 Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
03.12.07 Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
03.08.07 Callisto Pharmaceuticals Announces Patient Dosing in L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia
02.22.07 Callisto Pharmaceuticals Opens L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia
02.09.07 Callisto Pharmaceuticals to Present at BIO CEO & Investor Conference Wednesday 14 February 2007
01.31.07 Callisto Pharmaceuticals Opens Second Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
01.29.07 Callisto Notified by American Stock Exchange of Acceptance of Plan of Compliance and Extension to Regain Compliance With Standards
01.25.07 Callisto’s Cancer Drug Atiprimod to Be Presented at the Annual Meeting of American Association of Cancer Research
01.24.07 Callisto’s Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis
01.23.07 Publication of Early Research on Callisto Pharmaceutical’s Degrasyn Drug Class Suggests Potential to Treat Brain Tumors
01.05.07 Publication of Early Research on Callisto Pharmaceutical’s Degrasyn Drug Class Suggests Potential to Treat Brain Tumors
01.04.07 Callisto Pharmaceuticals CEO Releases Letter to Shareholders Describing Recent Accomplishments